Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study To Measure The Level Of Drug In Nasal Tissue And Blood After Taking A Single 2g Dose Or 500mg Tablets For Up To

This study has been completed.
Information provided by:
Pfizer Identifier:
First received: September 30, 2005
Last updated: April 20, 2011
Last verified: April 2011
To measure the level of drug in nasal tissue and blood after taking a single 2g dose or 500mg tablets for up to 3 days.

Condition Intervention Phase
Drug: Zithromax™ (azithromycin) 500mg tablets
Procedure: Endoscopic Sinus Surgery
Procedure: Blood sampling for hematology
Procedure: Blood sampling for plasma chemistry profile
Procedure: Serum pregnancy test (for women of child-bearing potential)
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: An Open-Label Study Of Azithromycin Pharmacokinetics In Sinus Mucosal Tissue And Plasma In Subjects With Chronic Rhinosinusitis Following A Single 2g Dose Of Azithromycin Extended Release For Oral Suspension Or Azithromycin 500mg Tablet Formulation Once Daily For A Maximum Of Three Days

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • To characterize the pharmacokinetics of azithromycin in sinus mucosal tissue and plasma in adult subjects after treatment with a single 2 g oral dose of azithromycin extended release for oral suspension or oral azithromycin 500 mg tablet

Secondary Outcome Measures:
  • To assess the safety of azithromycin extended release for oral suspension and azithromycin 500mg tablets.

Enrollment: 72
Study Start Date: November 2005
Study Completion Date: June 2006
Primary Completion Date: June 2006 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects considered by the Principal Investigator as an appropriate candidate for endoscopic sinus surgery, e.g., for the removal of the thickened and diseased mucosal tissue that blocks the ostiomeatal complex (OMC).

Exclusion Criteria:

  • Known or suspected hypersensitivity or intolerance to any macrolide-like compound, including erythromycin, clarithromycin, azithromycin or telithromycin.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00232154

United States, Alabama
Pfizer Investigational Site
Alabaster, Alabama, United States, 35007
Pfizer Investigational Site
Birmingham, Alabama, United States, 35209
Pfizer Investigational Site
Birmingham, Alabama, United States, 35233
Pfizer Investigational Site
Birmingham, Alabama, United States, 35242
Pfizer Investigational Site
Hoover, Alabama, United States, 35216
Pfizer Investigational Site
Hoover, Alabama, United States, 35244
United States, California
Pfizer Investigational Site
Fresno, California, United States, 93720
United States, Florida
Pfizer Investigational Site
Jacksonville, Florida, United States, 32216
Pfizer Investigational Site
Miami, Florida, United States, 33136-1002
United States, Georgia
Pfizer Investigational Site
Augusta, Georgia, United States, 30912
United States, Illinois
Pfizer Investigational Site
Elgin, Illinois, United States, 60120
Pfizer Investigational Site
Elgin, Illinois, United States, 60123
Pfizer Investigational Site
Maywood, Illinois, United States, 60153
United States, Kentucky
Pfizer Investigational Site
Carrollton, Kentucky, United States, 41008
Pfizer Investigational Site
La Grange, Kentucky, United States, 40031
Pfizer Investigational Site
Louisville, Kentucky, United States, 40207
United States, North Carolina
Pfizer Investigational Site
Durham, North Carolina, United States, 27710
United States, Pennsylvania
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information: Identifier: NCT00232154     History of Changes
Other Study ID Numbers: A0661151
Study First Received: September 30, 2005
Last Updated: April 20, 2011

Additional relevant MeSH terms:
Paranasal Sinus Diseases
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Anti-Bacterial Agents
Anti-Infective Agents processed this record on April 28, 2017